Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Zenas has made a $2 billion bet on autoimmune diseases with Chinese firm InnoCare, focusing on the development of orelabrutinib for multiple sclerosis. Former FDA director Peter Marks has joined Eli Lilly, marking the company's continued push in China. Sanofi's advancements in radiopharma, Boehringer Ingelheim's breakthrough in idiopathic pulmonary fibrosis, and Takeda's exit from cell therapy are also top stories. Cytiva filtration is highlighted as a solution for maintaining product integrity in biopharma.Biospace profiles the five most powerful women leading smaller biopharmaceutical companies, as the industry sees a shift with the departure of GSK CEO Emma Walmsley. A survey by CRB reveals that most life sciences companies are not planning new investments after tariffs, with big pharma taking the lead in manufacturing initiatives. Drug pricing criticism often overlooks the dynamic nature of drug pricing over time. Takeda's journey in building a cell therapy portfolio, only to ultimately walk away, is explored. Pfizer wins the bid for Metsera, Amgen offers Repatha at a discounted rate, and Roche acquires Akero for $3.5 billion. Biospace also honors 40 under 40 winners making an impact in the industry.Peter Marks, former director of the FDA's Center for Biologics Evaluation and Research, has taken on a new role as Senior Vice President for molecule discovery and the head of infectious diseases at Eli Lilly. Marks' controversial exit from the FDA led to his hiring by Lilly, following in the footsteps of another former FDA official, Rachael Anatol. Marks confirmed his new role to Stat News and began his first day at Lilly Research Laboratories on Monday.

Support the show